BACKGROUND: Management strategies for optic pathway gliomas include observation, surgery, irradiation, chemotherapy and a combination of these modalities. It has been the policy of our University Hospital to consider radiation as the standard treatment for progressive optic pathway gliomas. This report describes the clinical presentation, treatment patterns and outcome with special emphasis on the long term functional status of patients with optico-hypothalamic gliomas (OHG). PATIENTS AND METHODS: Between 1975 and 1997, 25 patients with OHG were treated by radiation therapy (RT) following surgery or biopsy. All patients received a local RT with a 0.5-1 cm margin around the lesions as depicted on CT or MRI scans. Age adjusted radiation doses ranged from 45 to 60 Gy with a single fraction size of 1.6-2 Gy. Endpoints of the study were: radiographic response, survival, progression-free survival and time to endocrinologic toxicity as well as the visual function during follow-up. The median follow-up time was 9 years (range, 1.5-23 years). RESULTS: A partial response was noted in six (24%) of the patients, 13 (52%) patients had a stable tumour throughout the observation period and six (24%) patients had a tumour progression. Overall survival and progression-free survival rates were 94 and 69% at 10 years, respectively. A significant influence on progression-free survival was noted for age at diagnosis (P=0.04) and total dose (P=0.05). Nine out of 13 (69%) patients aged below 10 years compared with 3/12 (25%) patients aged above 10 years experienced hypothalamic-pituitary deficiency (P=0.008) during follow-up. As for visual acuity, nine patients had an improvement, another 13 patients a stable situation and three patients a measurable deterioration. Visual field deficits improved in three, remained unchanged in 16 patients and worsened in only one patient. CONCLUSION: Postoperative RT with a total dose above 45 Gy should be considered as standard treatment in OHG with documented progression. Close radiographic monitoring and lifelong yearly evaluation for the need of possible hormone replacement are strongly recommended.
BACKGROUND: Management strategies for optic pathway gliomas include observation, surgery, irradiation, chemotherapy and a combination of these modalities. It has been the policy of our University Hospital to consider radiation as the standard treatment for progressive optic pathway gliomas. This report describes the clinical presentation, treatment patterns and outcome with special emphasis on the long term functional status of patients with optico-hypothalamic gliomas (OHG). PATIENTS AND METHODS: Between 1975 and 1997, 25 patients with OHG were treated by radiation therapy (RT) following surgery or biopsy. All patients received a local RT with a 0.5-1 cm margin around the lesions as depicted on CT or MRI scans. Age adjusted radiation doses ranged from 45 to 60 Gy with a single fraction size of 1.6-2 Gy. Endpoints of the study were: radiographic response, survival, progression-free survival and time to endocrinologic toxicity as well as the visual function during follow-up. The median follow-up time was 9 years (range, 1.5-23 years). RESULTS: A partial response was noted in six (24%) of the patients, 13 (52%) patients had a stable tumour throughout the observation period and six (24%) patients had a tumour progression. Overall survival and progression-free survival rates were 94 and 69% at 10 years, respectively. A significant influence on progression-free survival was noted for age at diagnosis (P=0.04) and total dose (P=0.05). Nine out of 13 (69%) patients aged below 10 years compared with 3/12 (25%) patients aged above 10 years experienced hypothalamic-pituitary deficiency (P=0.008) during follow-up. As for visual acuity, nine patients had an improvement, another 13 patients a stable situation and three patients a measurable deterioration. Visual field deficits improved in three, remained unchanged in 16 patients and worsened in only one patient. CONCLUSION: Postoperative RT with a total dose above 45 Gy should be considered as standard treatment in OHG with documented progression. Close radiographic monitoring and lifelong yearly evaluation for the need of possible hormone replacement are strongly recommended.
Authors: Andrea Maria Cappellano; Antonio Sergio Petrilli; Nasjla Saba da Silva; Frederico Adolfo Silva; Priscila Mendes Paiva; Sergio Cavalheiro; Eric Bouffet Journal: J Neurooncol Date: 2014-11-01 Impact factor: 4.130
Authors: Kristian Aquilina; David J Daniels; Helen Spoudeas; Kim Phipps; Hoong-Wei Gan; Frederick A Boop Journal: Childs Nerv Syst Date: 2015-08-16 Impact factor: 1.475
Authors: Martin Benesch; Herwig Lackner; Petra Sovinz; Elisabeth Suppan; Wolfgang Schwinger; Hans-Georg Eder; Hans Jürgen Dornbusch; Andrea Moser; Karin Triebl-Roth; Christian Urban Journal: J Neurooncol Date: 2006-04-25 Impact factor: 4.130
Authors: Joel M Cherlow; Dennis W W Shaw; Linda R Margraf; Daniel C Bowers; Jie Huang; Maryam Fouladi; Arzu Onar-Thomas; Tianni Zhou; Ian F Pollack; Amar Gajjar; Sandy K Kessel; Patricia L Cullen; Kevin McMullen; John C Wellons; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-10 Impact factor: 7.038
Authors: Richard M Awdeh; Erin N Kiehna; Richard D Drewry; Natalie C Kerr; Barrett G Haik; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant Journal: Int J Radiat Oncol Biol Phys Date: 2012-05-18 Impact factor: 7.038
Authors: K Müller; A Gnekow; F Falkenstein; J Scheiderbauer; I Zwiener; T Pietsch; M Warmuth-Metz; J Voges; G Nikkhah; M Flentje; S E Combs; D Vordermark; M Kocher; R-D Kortmann Journal: Strahlenther Onkol Date: 2013-07-07 Impact factor: 3.621